Anne C. Andorn, MD
Global Research & Development, Indivior Inc., North Chesterfield, Virginia
Original Research
Response to Subcutaneous Injectable Monthly Risperidone (RBP-7000): PANSS Item-Level Analysis
September 21, 2021
Phase 3 study data on the efficacy of RBP-7000 for schizophrenia were examined to see if dose-response relationships exist for different items of the Positive and Negative Syndrome Scale.
